trial · primary record
Dose Level 1, VNX-101
B-cell Acute Lymphoblastic Leukemia
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 32 |
| Primary completion | 2031-09 |
| Primary endpoint | Treatment emergent adverse events (TEAEs) and treatment-emergent serious events (TESAEs) |
| Registry ID | NCT06533579 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:40.152Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06533579
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.